T. Rowe Price Investment Management Adds $238M in Dyne Therapeutics, Inc. ($DYN)
Key Points
- T. Rowe Price Investment Management changed its Dyne Therapeutics, Inc. ($DYN) stake by 75.5% last quarter, boosting to 30,785,801 shares worth $552.61 million.
- Wall Street's consensus rating on $DYN is Strong Buy and an average price target of $38.25.
- $DYN last traded around $17.95.
T. Rowe Price Investment Management increased its position in Dyne Therapeutics, Inc. ($DYN) by 75.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,785,801 shares of Dyne Therapeutics, Inc. after buying 13,245,712 shares during the quarter. T. Rowe Price Investment Management's holdings in Dyne Therapeutics, Inc. were worth $552.61 million as of its most recent filing.
Dyne Therapeutics, Inc. ($DYN) Stock
Dyne Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.